There have been several noteworthy developments in the drug space recently, which will likely have a material impact on the companies in this sector and the markets they serve. Companies mentioned in this review include Eli Lilly & Co.
(LLY), Bristol-Myers Squibb
(BMY), Merck & Co.
(MRK), Pfizer Inc.
(PFE), Actavis plc.
(ACT), AbbVie Inc.
(ABBV), and Shire plc.
The equity bull market
is now somewhat long in the tooth and, as it makes its way through its sixth straight year, the going has not been as easy as it was in the early part of this run. The Dow Jones Industrials
have posted solid
, if relatively unexciting, numbers
through the first three quarters, but the Dogs
have maintained an edge
throughout most of that period.
There are a handful of companies
in the restaurant space
that do not report results on a calendar-year basis, so we will take a look at their recent performances to try and get a better picture of what is to come in the next few weeks.
Gaming’s growth in Macau, China has made many Asian countries envious. Eager to replicate the success of the world’s biggest gaming market, a number of nations in the Pacific region have/are contemplating the approval for integrated casino resorts. None of them offer the potential of Japan, whose population possess high earnings and have a proclivity for gaming. Moreover, should the economic juggernaut approve the building of such establishments, it is apt to attract gaming enterprises from across the world.
There have been several noteworthy developments in the technology space recently. Some of these will likely have a material impact on the companies in the sector and the markets they serve. Companies featured include Sony (SNE), Apple (AAPL), Samsung, and eBay (EBAY).
has fallen out of grace
in recent years
. Should investors
be excited about new developments
in this once promising alternative fuel
Preliminary results for the recently ended back-to-school season look to be better-than-originally-expected for most in the retail space. Indeed, August sales
were said to have increased 0.3%, ahead of Wall Street’s call. Although the advance was minor, overall, many are speculating that the August outperformance may be an inflection point, and that an improved housing market, lower fuel costs, and more favorable job market have helped lift consumer confidence to levels not seen in recent memory.
have pulled back
as demand growth
and supplies have increased. But volatility
is par for the course in the drilling business
, and the pendulum may well swing back the other way before too long.
There have been several noteworthy developments
in the drug space
recently, which will likely have a material impact on the companies in this sector and the markets they serve. Companies mentioned in this review include Pfizer Inc
. (PFE), AstraZeneca
(AZN), Merck & Co.
(MRK), AbbVie Inc
. (ABBV), and Eli Lilly
As the U.S. bull market
for equities marches toward a sixth straight year, major benchmarks
such as the S&P 500
and Dow Jones Industrials
have clawed their ways to new highs
. However, the numbers alone don’t tell the whole story. The Dogs of the Dow strategy
, unsurprisingly, is also benefitting from the upswing, advancing every month with the exception of January. Although August found the pack lagging the gains posted by the 30 Dow Industrials as a whole, year-to-date performance has maintained a relatively comfortable lead. Merck
logged the biggest gains last month, but Intel’s stock has outrun the Dogs (and the rest of the Dow components, for that matter) by a sizable margin so far this year.